Lilly/Icos Cialis Trial In Benign Prostatic Hyperplasia To Start This Year
Executive Summary
Lilly/Icos hopes results from a Phase II trial evaluating Cialis in benign prostatic hyperplasia will help position the erectile dysfunction therapy as the "treatment of choice," Icos told investors May 3
You may also be interested in...
“Cialis Challenge”: ED Drug Sampling Hides True Market Growth, Icos Says
Increased prescription sampling within the erectile dysfunction market has caused an understatement of the category's overall growth, Icos VP-Sales & Marketing Leonard Blum told investors May 3
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials